POTENTIAL COMPLICATIONS
Generally, percutaneous biliary tract interventions
are associated with complication rates ranging from
3% to 10% and procedural mortality rates ranging
from 0.1% to 0.8% [19]. Although safe, PTBD
and stenting of malignant biliary obstruction is
associated with immediate, early (within 30 days) or
late complications. The incidence of complications
ranges from 8%42% in which 5.9% of patients
suffered a complication within 7 days of their PTBD
and 20% within 3 months [2,7]. Infection was the
most common complication with 2.4% of patients
experiencing this within a week, and 9% within a
month (cholangitis 3.9%, sepsis 3.9%, bacterial
infection of unspecified site 0.8%, cholecystitis
0.4%) [2,19]. Minor complications are pain at the
puncture site, bile leak with risk of biliary peritonitis
and biloma formation and catheter related problems
like kinking or dislocation [6]. Major complications
include sepsis (2.5%), haemobilia (2.5%), arterial
injury (1-2%), overall inflammation (abscess,
peritonitis, cholecystitis, acute pancreatitis: 1.2%),
pneumothorax (0.5%), acute kidney injury (0.9%)
and death (1.7%) [2,7,11,19].
The reported rate of significant bleed after
PTBD varies from 0.6% to 12% [20]. For patient
requiring hemostasis correction, the risk of bleeding
is also acceptable (15.8%) [21]. Bile leak is another
common complaint (6%) in clinical setting [3,11].
The causes are various including ascites, catheter
blockage or malposition [3,6,11]. A cholangiogram
is needed to evaluate the catheter position and
patency. Based on the findings, reposition, change
or larger bore catheters upgrade will be considered.
Seeding metastasis has been reported elsewhere
but has a high incidence in Japan (4-40.4%) [22].
A meta-analysis showed that EBD was associated
with fewer seeding metastasis than PTBD (10.5%
vs. 22.0%, P< 0.01) [22].
Stent blockage may occur due to tumor
ingrowth, tumor overgrowth or sludge. This
needs repeat procedure. PTBD can be done again
and a ring biliary catheter or another stent can be
placed through the blocked stent [6]. Recurrent
cholangitis due to stent occlusion is seen in about
30% cases, which needs repeat stenting [6]. The
stent patency rates are higher for metallic stents
(85%) compared with plastic stents (67.6%) [23].
The recommended overall procedure threshold for
all major complications of PTBD is 10% [7].
11 trang |
Chia sẻ: hachi492 | Lượt xem: 16 | Lượt tải: 0
Bạn đang xem nội dung tài liệu Percutaneous transhepatic intervention for malignant biliary obstruction, để tải tài liệu về máy bạn click vào nút DOWNLOAD ở trên
Hue Central Hospital
Journal of Clinical Medicine - No. 64/2020 3
1. Department of Radiology, Hue University of Medicine
and Pharmacy, Hue University
2. Department of Surgery, Hue University of Medicine and
Pharmacy, Hue University
3. Department of Radiology, Hue University of Medicine
and Pharmacy Hospital, Hue, Vietnam
- Received: 2/6/2020; Revised: 10/7/2020;
- Accepted: 4/9/2020
- Corresponding author: Le Trong Binh
- Email: ltbinh.cdha@huemed-univ.edu.vn; Phone: 84905215096
Review
PERCUTANEOUS TRANSHEPATIC INTERVENTION FOR
MALIGNANT BILIARY OBSTRUCTION
Le Trong Binh1*, Tran Van Khoi2, Hoang Anh Dung1,
Huyen Ton Nu Hong Hanh3, Le Nguyen Pon1, Le Minh Tuan1, Dang Quang Hung3
DOI: 10.38103/jcmhch.2020.64.1
ABSTRACT
Biliary obstruction is a serious clinical condition resulting from either benign or malignant etiologies. For
malignant obstruction, curative resection is rarely performed due to disease progression, thus decompression
drainage is the management of choice. Percutaneous transhepatic drainage and stenting are effective
alternative treatments to surgical bypass and endoscopic biliary drainage when these two modalities are
contraindicated. Percutaneous biliary intervention is safe and effective in both drainage and restoration of
bile flow with high successful rate and acceptable risk of complication. Multidisciplinary approach, proper
patient selection, careful image review and comprehensive knowledge of available techniques, success
rates and complications are utmost importance for a successful procedure.
Key words: malignant biliary obstruction, percutaneous transhepatic biliary drainage, stenting
I. INTRODUCTION
Biliary obstruction is a serious condition that can
occur in the setting of both benign and malignant
pathologies, leading to life quality impairment,
pruritus, cholangitis and liver failure [1-3]. Malignant
biliary obstruction most commonly results from
pancreatic adenocarcinoma and cholangiocarcinoma,
followed by gallbladder carcinoma, hepatocellular
carcinoma, lymphoma, liver metastasis and perihilar
lymphadenopathy [4,5].
Curative resection is the primary goal of treatment
but rarely possible because of local invasion and
distant metastases at the time of diagnosis [2,4].
Therefore, palliative decompression of advanced
malignant obstruction by biliary catheterization or
stent placement remains a key component in the
management of these patients [4]. Decompression
of the biliary system relieves pain, decreases
jaundice and risk of cholangitis, improves liver
function prior to curative therapy, and provides a
bridge to palliative chemotherapy [6]. Restoration
of the biliary to bowel transit also allows
physiological bile flow [6]. Biliary drainage can be
achieved from surgical bypass, endoscopic biliary
drainage (EBD) or percutaneous transhepatic
cholangiography depending on the etiology and
the chance for cure [2,4]. Importantly, the most
Bệnh viện Trung ương Huế
4 Journal of Clinical Medicine - No. 64/2020
Percutaneous Transhepatic Intervention for Malignant Bilia y Obstruction
effective strategy to manage malignant biliary
obstruction should combine a multidisciplinary
team of hepatobiliopancreatic surgeons, medical
oncologists, diagnostic radiologists, surgical
oncologists, gastroenterologists, and interventional
radiologists [4].
Percutaneous transhepatic biliary drainage
(PTBD) is a therapeutic procedure that includes the
sterile cannulation of a peripheral biliary radicle
or an intrahepatic duct (IHD) after percutaneous
puncture followed by imaging-guided wire and
catheter manipulation. Placement of a tube or stent
for external and/or internal drainage completes the
procedure. Percutaneous therapy of biliary lesions
is often staged, requiring several sessions to achieve
the therapeutic goals [7]. Since its introduction
in the late 1960s, PTBD has been used globally
to treat biliary obstruction of both benign and
malignant causes [1,8]. The procedure is especially
beneficial for patients who are not candidates for
curative operation or endoscopic intervention.
Surgical bypass demonstrated low rates of recurrent
jaundice (2-5%), however, the surgery itself carries
an appreciable risk of postoperative morbidity
and mortality, in up to ¼ of the patients in some
trials [5]. In cases of malignant biliary obstruction,
the first choice of treatment worldwide is EBD.
However, EBD is not always feasible due to
duodenal obstruction or previous surgery that has
altered the anatomy. Under these circumstances,
and in cases where prior EBD has been insufficient
or failed, PTBD is often a suitable treatment option
[9,10]. This procedure is a potential option for any
case of biliary obstruction, but always first line for
malignant lesions above the level of the common
hepatic duct, particularly for advanced unresectable
hilar malignant biliary obstruction [2,4]. This article
aims to highlights the perspectives of radiological
intervention for malignant biliary obstruction.
Clinical cases from Hue University of Medicine and
Pharmacy Hospital are also illustrated.
II. INDICATIONS AND
CONTRAINDICATIONS OF PTBD
PTBD is performed as a pre operative procedure
for resectable malignancies, prior to neoadjuvant
chemotherapy or as a palliative technique [6].
Indications of PTBD are based on the practice
guideline of the Society of Interventional
Radiology [7], as followed:
- Provide adequate biliary drainage
+ Decompress obstructed biliary tree
+ Divert bile from and place stent in bile
duct defect
- Provide a portal of access to the biliary tract
for therapeutic purposes that include but are not
limited to:
+ Dilate biliary strictures
+ Remove bile duct stones
+ Stent malignant lesions
+ Brachytherapy/phototherapy
+ Endoluminal tissue sample or foreign body
retrieval
- Provide a portal of access to the biliary tract for
mid-to long-term diagnostic purposes (lower-risk
cholangiography)
Coagulopathy is a relative contraindication to
PTBD. Every effort should be made to correct or
improve coagulopathy before the procedure. In patients
with persistent coagulopathy, these procedures may still
be indicated if they are associated with a lower expected
morbidity rate than alternative methods of diagnosis or
treatment [7]. Other relative contraindications include
INR >1.5, platelet count < 50,000 x 109/L, ascites and
multiple hepatic cysts [11].
III. TECHNIQUES OF PTBD
Patient consent must be obtained prior to any
procedure. Prophylactic antibiotic should be instituted
before and after the procedure, as manipulations
in obstructed system carry the risk of cholangitis and
sepsis. For pain alleviation, intravenous analgesics can
Hue Central Hospital
Journal of Clinical Medicine - No. 64/2020 5
be administered or optionally the procedure can be
performed under conscious sedation. Fasting for at
least 4 h prior to the procedure is necessary [11].
We routinely perform PTBD using Seldinger
technique (Figure 1) with a micro puncture set (Neff
set, Cook medical, Bloomington, IN, USA).
- Patient is in supine position. After sterile
preparation, local anesthesia is given at the expected
puncture site.
- A dilated peripheral duct is targeted using a
22G Chiba needle under ultrasound guidance. A
small amount of contrast medium is injected to
confirm the bile duct. A 0.018” hair wire is then
advanced through the needle to the bile duct under
fluoroscopic guidance.
- A small skin incision is made and the tract
is created followed by an introduction of a 5F
sheath. Cholangiography is performed to evaluate
the biliary tree (anatomy, obstruction site, type
of obstruction, filling defect, common bile duct
patency, bile leak).
- A 0.035” hydrophilic wire (Terumo, Tokyo,
Japan) is used to cross the obstruction. An
angiographic catheter (usually Cobra 5F) can be
used to help manipulate the guide wire. Once the
wire is across the stricture and in the duodenum, the
catheter is pushed over the wire into the duodenum.
The soft wire is then replaced by a Super Stiff
Amplatz guide wire (Boston scientific, Natick, MA,
USA) over which the tract and stricture are dilated
Figure 1: Pre-operative PTBD using Seldinger technique in a patient with ampullary cancer. (A) A
segmental IHD dilatation was seen on ultrasound (arrow). (B) Ultrasound-guided puncture of the selected
IHD. Contrast medium was injected to confirm the IHD and a 0.018” hair wire was advanced to the distal
common bile duct (CBD) under fluoroscopic guidance. (C) A 5F sheath was introduced over the wire and
cholangiography was performed to evaluate the biliary tree anatomy and pathologies. (D) A 0.035” J tip
hydrophilic wire was manipulated across the obstruction site to the distal CBD followed by an introduction
of an angiographic catheter. (E) Cholangiography of the downstream CBD was done. (F) The tract was
dilated with an 8F dilator. (G) An 8F pigtail drainage catheter was advanced over the wire and positioned
in the distal CBD. (H) Completion cholangiography and aspiration were performed to confirm the desired
catheter position and function.
Bệnh viện Trung ương Huế
6 Journal of Clinical Medicine - No. 64/2020
Percutaneous Transhepatic Intervention for Malignant Biliary Obstruction
with an 8F dilator. Finally, a drainage catheter (8F,
10F) is positioned across the stricture. A completion
cholangiography and aspiration are performed to
confirm the position and the function of the catheter.
- The catheter can be placed proximally to the
obstruction site for external drainage or distally
for internal-external drainage (Figure 2). In the
latter case, multiple side holes are created on the
drainage catheter to ensure effective drainage of
both upstream and downstream biliary tract.
Figure 2: External drainage and external-inter-
nal drainage of the same patient. (A, C): Magnet-
ic retrograde cholangiopancreatography (MRCP)
image and cholangiogram of an external drainage
for a malignant hilar obstruction. (B, D): Follow-up
MRCP and external-internal drainage catheter was
exchanged. Multiple side hole were created along
the catheter to optimize drainage efficacy.
Depending on the type and extent of the
obstruction, patient status, unilateral or bilateral
drainage (T vs. Y configuration) will be decided
(Figure 3, 4). Multiple segment drainage may
also be performed when secondary confluence is
involved. In case of chronically obstructed biliary
segments with parenchymal atrophy, except for
biliary infection, drainage is usually ineffective
since improvement of liver function is unlikely [6].
Figure 3: Unilateral PTBD with T-configuration
catheter in a patient with multiple liver metastases.
The biliary tree was approached from the segment
3 (B3), from which 2 drainage catheters were
inserted, one to the right IHD and the other to the
CBD. Multiple side holes were also created. Noted
a good passage of contrast medium through 2
previously inserted CBD metallic stents.
Figure 4: Bilateral
PTBD with Y-configuration
drainage catheters for
the management of a type
II Klatskin tumor. Left
IHD was accessed from
segment 3 and right IHD
from segment 6. Catheter
tips were positioned in the
distal CBD across the hilar
obstruction. Multiple side
holes were made to ensure
external-internal drainage.
Hue Central Hospital
Journal of Clinical Medicine - No. 64/2020 7
- The drainage catheter is secured to the skin and
attached to a urine bag through a 3-way stopcock
to facilitate daily irrigation or sampling. Saline
irrigation is recommended twice daily thereafter.
Left vs. right-sided PTBD
The procedure can be performed either via right
(subcostal or intercostal) or left ductal (subxiphoid)
approach. Selection of appropriate sided duct is
down to operator preference, although there are
certain advantages and disadvantages of both (Table).
Castiglione found that right access is associated with
intercostal pain and respiratory difficulties whereas left
access for PTBD provides a better Quality of Life for
patients who underwent PTBD as palliative treatment
for the management of malignant obstructive jaundice
and could be considered as the approach of choice in
case of distal obstruction [12]. Reviewing ultrasound
prior to biliary puncture is crucial for assessing the
suitability of puncture as well as any contraindication
to the procedure [11].
Table 1: Comparison between left-sided vs. right-sided IHD puncture
Left-sided puncture Right-side puncture
Advantages
Easier to puncture
Better patient’s compliance
More preferable in ascites
Less radiation exposure to operator’s hand
More liver segment drainage
Disadvantages More radiation exposure to operator’s hand
More painful due to continuous irritation of
intercostal nerves
More chances of accidental catheter dislodge
due to constant motion of the drainage catheter
in the intercostal space during respiration
Biliary stenting
Once the obstruction is traversed, stent can be deployed to recanalize bile flow. Self-expandable metallic
stents are more preferable due to their higher patency rates (Figure 5). We usually insert stents 1-2 weeks after
the 1st PTBD to prevent complication (cholangitis) (Figure 6). The proximal and distal ends of the stent should
be at least 1 cm and preferably 2 cm from the proximal and distal ends of obstruction, respectively [6].
Figure 5: Biliary stenting in a patient with distal CBD cancer. Follow-up cholangiogram
through a pigtail catheter confirmed the patency of the bile flow.
Bệnh viện Trung ương Huế
8 Journal of Clinical Medicine - No. 64/2020
We sometimes pre-dilate the obstruction site with
low pressure balloon to facilitate stent passage. The
metallic stents have thermal memory and expand to
their maximum width when they reach the body tem-
perature, usually occurring in 24 48h. If the expansion
is not adequate after 48h, dilatation of the stent with
balloon catheter may be needed for successful drain-
age. Self-expandable metallic stents can be either
covered or uncovered. Uncovered stents are usually
preferred due to their lower costs, very low incidence
of migration and lower complications of cholangitis
and pancreatitis but have higher incidence of tumor
ingrowth [6]. The patency rate for uncovered stents is
about 70% at 6 months and 50% at 1 year.
Figure 6: PTBD and CBD stenting in a patient presented with biliary septic shock. He was previously
treated with surgical bypass due to pancreatic head cancer. PTBD was performed for decompression
followed by CBD stents deployment to maintain the bile flow.
One study showed that performing PTBD
and stenting as a “one-stage” procedure is
useful, safe, and cost-effective with a high
percentage of technical success and a similar
occurrence of complications compared to the
two-stage procedure [13]. Like PTBD, stent can
be inserted unilaterally or bilaterally with a T or
Y-configuration (Figure 7, 8, 9).
Figure 7: Bilateral biliary stenting with Y-configuration in a patient with type II Klastkin tumor. Noted
that 2 drainage catheters were left in place for at least 1 week post stenting to ensure full expansion of the
metallic stents.
Percutaneous Transhepatic Intervention for Malignant Biliary Obstruction
Hue Central Hospital
Journal of Clinical Medicine - No. 64/2020 9
IV. OUTCOMES OF PTBD
Technical success rate of PTBD is 95% for dilated
duct and 70% for non-dilated duct [7] and clinical
success is >75% [12]. A recent study reported
technical success of PTBD was 91.2% in high risk
patients and concluded that PTBD can be effectively
and safely performed even in situations which
potentially increase risk of adverse events [10].
Drainage of 25% 30% of normal liver is adequate to
improve jaundice and liver functions [6].
Figure 8: Bilateral T-stent for the management of type II hilar obstruction. (A, B) T2W FS MRI and
MRCP showed a mass-forming and an intraductal tumor causing prominent left IHD dilatation. (C) A
left-to-right PTBD was performed with multiple side holes. Cholangiogram demonstrated a filling defect
at the confluence. (D) Intraoperative biopsy was performed which later confirmed the diagnosis of
cholangiocarcinoma. (E, F) A left-to-right stent was deployed. Cholangiogram showed patency of stent.
Note the filling defect within the stent (tumor ingrowth) and severe stricture of the common hepatic duct
and proximal CBD. (G) A left-to-CBD stent was subsequently inserted through the struts of the initial stent.
(H) Follow-up cholangiogram confirmed the stent patency without IHD dilatation. The drainage catheter
was removed shortly.
Data comparing PTBD and EBD as an initial
procedure prior to surgery are inhomogeneous. A
meta-analysis shows that PTBD has a lower rate of
complications than EBD as an initial procedure and
is associated with less conversion and lower rates
of pancreatitis and cholangitis [14]. Conversely,
Mori et al concluded that PTBD is significantly
associated with shorter survival and peritoneal
recurrence and should not be performed for patients
undergoing pancreatoduodenectomy [15]. Another
study observed a similar median decrease in total
bilirubin levels after biliary drainage between
PTBD vs. EBD and these 2 modalities had similar
long-term disease-specific survival and recurrence-
free survival [16]. However, another study found
that bilirubin decreased from 237 µmol/l (31-634)
to 180 µmol/l (17-545) within the first week after
PTBD and only 25% reached a level below the
double upper reference value while adverse events
are common [17].
Bệnh viện Trung ương Huế
10 Journal of Clinical Medicine - No. 64/2020
A study group enrolled 643 patients with
malignant biliary obstruction found that median
overall survival (OS) after PTBD was 2.6 months
(95% CI 2.2–3.0), and 108 patients (16.8%) were
alive at 12 months post-drainage [9]. Median
overall survival was better in patients with biliary
obstruction due to primary cancer compared to
patients with biliary obstruction due to metastases
((3.5 months vs. 1.5 months, respectively) [9].
Survival is 2–6 times better in patients with
good performance status and who can undergo
chemotherapy after biliary drainage compared to
patients unable to receive chemotherapy [18].
A large scale national cohort reported high
30-day mortality rate (23.1%) after PTBD for
malignant biliary obstruction, in which 5.2% died
within 7 days and 15.3% died in hospital [2].
V. ASSOCIATED FACTORS OF BETTER
OUTCOME POST DRAINAGE
Factors associated with 30- day mortality were
age (≥81 years), increasing comorbidity, pre-
existing renal dysfunction and non- pancreatic
cancer [2]. Higher median survival was associated
with age ≤ 75 years, lower ASA class, lower ECOG
performance status, obstruction due to primary
cancer, and bilirubin level <60.0 µmol/L [9]. ECOG
PS was an independent factor for predicting OS [9].
Prognosis was extremely poor for patients with an
ECOG PS of 3 or 4 (median OS was 0.9 months)
and better for those with an ECOG of 2 (median OS
was 1.7 months) [9]. In clinical practice, patients
with ECOG PS of >2 are generally not candidates
for chemotherapy and are treated with palliative
care and minimal interventions.
Figure 9: PTBD and bilateral stenting using T-configuration. (A) MRCP image showed extensive IHD
dilatation due to type IV Klatskin tumor. (B). Cholangiogram demonstrated severe stricture at the confluence
extended to the bilateral lobar hepatic duct, consistent with type IV Klatskin cholangiocarcinoma. (C) An
8F vascular sheath was placed at the segment 3 IHD followed by an introduction of 2 hydrophilic wire
(double wire technique), one to the right IHD and the other to the distal CBD. (D) A left-to-right metallic
stent was deployed and post-dilated with a balloon. (E) Next, a left-to-CBD stent was deployed across the
mesh of the 1st stent. (F) A drainage catheter was remained in the CBD stent. (G) Spot image of the bilateral
T-stent. (H) Follow-up cholangiogram showed full stent expansion and good bile flow without evidence of
IHD dilatation. The drainage catheter was removed thereafter.
Percutaneous Transhepatic Intervention for Malignant Biliary Obstruction
Hue Central Hospital
Journal of Clinical Medicine - No. 64/2020 11
Post-drainage bilirubin level < 60 µmol/L was
associated with longer survival, thus this parameter
can be used to predict survival [9]. Patients with
high bilirubin levels before drainage can achieve
clinically relevant bilirubin reduction. High
bilirubin levels are usually a contraindication for
chemotherapy, and thus a reduction in bilirubin
level may enable future chemotherapy treatment
[9]. However, Thornton et al. reported that only
31% of patients achieved post-drainage bilirubin
levels low enough to permit chemotherapy.
VI. POTENTIAL COMPLICATIONS
Generally, percutaneous biliary tract interventions
are associated with complication rates ranging from
3% to 10% and procedural mortality rates ranging
from 0.1% to 0.8% [19]. Although safe, PTBD
and stenting of malignant biliary obstruction is
associated with immediate, early (within 30 days) or
late complications. The incidence of complications
ranges from 8% 42% in which 5.9% of patients
suffered a complication within 7 days of their PTBD
and 20% within 3 months [2,7]. Infection was the
most common complication with 2.4% of patients
experiencing this within a week, and 9% within a
month (cholangitis 3.9%, sepsis 3.9%, bacterial
infection of unspecified site 0.8%, cholecystitis
0.4%) [2,19]. Minor complications are pain at the
puncture site, bile leak with risk of biliary peritonitis
and biloma formation and catheter related problems
like kinking or dislocation [6]. Major complications
include sepsis (2.5%), haemobilia (2.5%), arterial
injury (1-2%), overall inflammation (abscess,
peritonitis, cholecystitis, acute pancreatitis: 1.2%),
pneumothorax (0.5%), acute kidney injury (0.9%)
and death (1.7%) [2,7,11,19].
The reported rate of significant bleed after
PTBD varies from 0.6% to 12% [20]. For patient
requiring hemostasis correction, the risk of bleeding
is also acceptable (15.8%) [21]. Bile leak is another
common complaint (6%) in clinical setting [3,11].
The causes are various including ascites, catheter
blockage or malposition [3,6,11]. A cholangiogram
is needed to evaluate the catheter position and
patency. Based on the findings, reposition, change
or larger bore catheters upgrade will be considered.
Seeding metastasis has been reported elsewhere
but has a high incidence in Japan (4-40.4%) [22].
A meta-analysis showed that EBD was associated
with fewer seeding metastasis than PTBD (10.5%
vs. 22.0%, P< 0.01) [22].
Stent blockage may occur due to tumor
ingrowth, tumor overgrowth or sludge. This
needs repeat procedure. PTBD can be done again
and a ring biliary catheter or another stent can be
placed through the blocked stent [6]. Recurrent
cholangitis due to stent occlusion is seen in about
30% cases, which needs repeat stenting [6]. The
stent patency rates are higher for metallic stents
(85%) compared with plastic stents (67.6%) [23].
The recommended overall procedure threshold for
all major complications of PTBD is 10% [7].
VII. CONCLUSION
Percutaneous management of malignant biliary
obstruction is a well-established method of treatment.
Although long-term prognosis remains dismal
in malignant obstructive jaundice, percutaneous
biliary intervention is the recommended standard
of palliative care as it improves quality of life with
definite immediate survival benefits and facilitate
resection or adjuvant chemotherapy. Careful image
reviewing, appropriate pre-procedure planning
and multidisciplinary discussions are crucial for
optimal patient management. A comprehensive
knowledge of the available techniques, success
rates and risk of complications is needed for a
successful procedure.
VIII. DISCLOSURE
The authors declare no potential conflict of
interest.
Bệnh viện Trung ương Huế
12 Journal of Clinical Medicine - No. 64/2020
1. Expert Panel on Interventional R, Fairchild
AH, Hohenwalter EJ, Gipson MG, Al-Refaie
WB, Braun AR, et al. ACR Appropriateness
Criteria((R)) Radiologic Management of
Biliary Obstruction. J Am Coll Radiol
2019;16:S196-S213
2. Rees J, Mytton J, Evison F, Mangat KS, Patel P,
Trudgill N. The outcomes of biliary drainage by
percutaneous transhepatic cholangiography for
the palliation of malignant biliary obstruction in
England between 2001 and 2014: a retrospective
cohort study. BMJ Open 2020;10:e033576
3. Rasekhi A, Kondori NB. Causes and Treatment of
Bile Leaks at the Puncture Site After Percutaneous
Transhepatic Biliary Decompression. American
Journal of Interventional Radiology 2019;3:8
4. Lorenz JM. Management of Malignant
Biliary Obstruction. Semin Intervent Radiol
2016;33:259-267
5. Pu LZ, Singh R, Loong CK, de Moura EG.
Malignant Biliary Obstruction: Evidence
for Best Practice. Gastroenterol Res Pract
2016;2016:3296801
6. Madhusudhan KS, Gamanagatti S, Srivastava
DN, Gupta AK. Radiological interventions in
malignant biliary obstruction. World J Radiol
2016;8:518-29
7. Saad WE, Wallace MJ, Wojak JC, Kundu S,
Cardella JF. Quality improvement guidelines
for percutaneous transhepatic cholangiography,
biliary drainage, and percutaneous
cholecystostomy. J Vasc Interv Radiol
2010;21:789-95
8. Tuqan W, Innabi A, Alawneh A, Farsakh FA,
Al-Khatib M. Prediction of Survival Following
Percutaneous Biliary Drainage for Malignant Biliary
Obstruction. J Transl Int Med 2017;5:127-131
9. Niemela J, Kallio R, Ohtonen P, Perala J, Saarnio
J, Syrjala H. Is Palliative Percutaneous Drainage
for Malignant Biliary Obstruction Useful? World
J Surg 2018;42:2980-2986
10. Gupta P, Maralakunte M, Rathee S, Samanta J,
Sharma V, Mandavdhare H, et al. Percutaneous
transhepatic biliary drainage in patients at higher
risk for adverse events: experience from a
tertiary care referral center. Abdom Radiol (NY)
2020;45:2547-2553
11. Chandrashekhara SH, Gamanagatti S, Singh A,
Bhatnagar S. Current Status of Percutaneous
Transhepatic Biliary Drainage in Palliation of
Malignant Obstructive Jaundice: A Review.
Indian J Palliat Care 2016;22:378-387
12. Castiglione D, Gozzo C, Mammino L, Failla G,
Palmucci S, Basile A. Health-Related Quality of
Life evaluation in “left” versus “right” access
for percutaneous transhepatic biliary drainage
using EORTC QLQBIL-21 questionnaire: a
randomized controlled trial. Abdom Radiol
(NY) 2020;45:1162-1173
13. Fucilli F, Licinio R, Lorusso D, Giorgio P, Caruso
ML. One stage percutaneous transhepatic biliary
stenting for malignant jaundice: a safe, quick
and economical option of treatment. Eur Rev
Med Pharmacol Sci 2019;23:7684-7693
14. Al Mahjoub A, Menahem B, Fohlen A, Dupont
B, Alves A, Launoy G, et al. Preoperative
Biliary Drainage in Patients with Resectable
Perihilar Cholangiocarcinoma: Is Percutaneous
Transhepatic Biliary Drainage Safer and More
Effective than Endoscopic Biliary Drainage?
A Meta-Analysis. J Vasc Interv Radiol
2017;28:576-582
15. Mori S, Aoki T, Park KH, Shiraki T, Sakuraoka
Y, Iso Y, et al. Impact of preoperative
percutaneous transhepatic biliary drainage
on post-operative survival in patients with
distal cholangiocarcinoma. ANZ J Surg
2019;89:E363-E367
REFERENCES
Percutaneous Transhepatic Intervention for Malignant Biliary Obstruction
Hue Central Hospital
Journal of Clinical Medicine - No. 64/2020 13
16. Zhang XF, Beal EW, Merath K, Ethun CG,
Salem A, Weber SM, et al. Oncologic effects
of preoperative biliary drainage in resectable
hilar cholangiocarcinoma: Percutaneous biliary
drainage has no adverse effects on survival. J
Surg Oncol 2018;117:1267-1277
17. Heedman PA, Astradsson E, Blomquist K,
Sjodahl R. Palliation of Malignant Biliary
Obstruction: Adverse Events are Common after
Percutaneous Transhepatic Biliary Drainage.
Scand J Surg 2018;107:48-53
18. Afshar M, Khanom K, Ma YT, Punia P. Biliary
stenting in advanced malignancy: an analysis of
predictive factors for survival. Cancer Manag
Res 2014;6:475-9
19. Venkatanarasimha N, Damodharan K, Gogna
A, Leong S, Too CW, Patel A, et al. Diagnosis
and Management of Complications from
Percutaneous Biliary Tract Interventions.
Radiographics 2017;37:665-680
20. Quencer KB, Tadros AS, Marashi KB, Cizman Z,
Reiner E, O’Hara R, et al. Bleeding after Percutaneous
Transhepatic Biliary Drainage: Incidence, Causes
and Treatments. J Clin Med 2018;7
21. HOUGHTON EJ, INVERNIZZI E,
ACQUAFRESCA P, PALERMO M, GIMÉNEZ
ME. RISK OF BLEEDING COMPLICATIONS
IN PERCUTANEOUS BILIARY DRAINAGE:
THE PARADOX OF THE NORMAL
HEMOSTASIS. ABCD. Arquivos Brasileiros de
Cirurgia Digestiva (São Paulo) 2019;32
22. Wang L, Lin N, Xin F, Ke Q, Zeng Y, Liu J.
A systematic review of the comparison of
the incidence of seeding metastasis between
endoscopic biliary drainage and percutaneous
transhepatic biliary drainage for resectable
malignant biliary obstruction. World J Surg
Oncol 2019;17:116
23. Guo YX, Li YH, Chen Y, Chen PY, Luo PF, Li
Y, et al. Percutaneous transhepatic metal versus
plastic biliary stent in treating malignant biliary
obstruction: a multiple center investigation.
Hepatobiliary Pancreat Dis Int 2003;2:594-7
Các file đính kèm theo tài liệu này:
percutaneous_transhepatic_intervention_for_malignant_biliary.pdf